Living Proof Signs 14,085 SF Office, Life Sciences Lease in Boston’s Seaport District

Why this matters

Living Proof’s lease commitment in Boston’s Seaport District underscores a nuanced dynamic in the office sector, particularly within life sciences-adjacent markets. While broader US office fundamentals remain challenged by remote work trends and tenant downsizing, this deal signals continued demand for specialized office space tied to innovation clusters. The Seaport’s evolution into a hybrid office–life sciences hub reflects institutional capital’s strategic pivot toward assets that can capture growth from knowledge economy tenants. For allocators and lenders, the transaction highlights the importance of location and tenant quality in underwriting office leases amid persistent uncertainty. Life sciences and innovation-driven companies often require bespoke space and demonstrate more resilient occupancy profiles, which can mitigate downside risk relative to traditional office users. This lease may also indicate selective leasing activity that supports valuations in submarkets benefiting from amenity-rich environments and proximity to research institutions. In capital markets terms, such deals reinforce the bifurcation within office real estate: prime, innovation-focused submarkets continue to attract tenant demand and investor interest, while secondary markets face greater headwinds. The Living Proof lease thus serves as a barometer for where institutional capital is likely to concentrate in the evolving office landscape.

Editorial analysis · AI-assisted

On the RET wire

• The 39th Boston story tracked on the wire in June 2026. All Boston coverage →
• Disclosed office deal value tracked in June 2026: $9.2B across 60 reported transactions. All Office coverage →

Computed from Real Estate Trail’s own tracked coverage

External link. Real Estate Trail does not republish source content.